Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Pinocembrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.95 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.95 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.95 |
| ▸ | MAPT | P10636 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | TTR | P02766 | 4/20 | 0.78 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.78 |
| ▸ | CA12 | O43570 | 2/20 | 0.78 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.78 |
| ▸ | CA4 | P22748 | 2/20 | 0.78 |
| ▸ | CA7 | P43166 | 2/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pinocembrin SCHEMBL291899 | 0.97 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| (R)-Pinocembrin SCHEMBL10080882 | 0.97 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Pinocembrin SCHEMBL30186539 | 0.97 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Pinocembrin SCHEMBL10026578 | 0.97 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Pinocembrin SCHEMBL2484359 | 0.96 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Pinocembrin SCHEMBL3437711 | 0.91 | CYP19A1 (0.88) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL1333765 | 0.88 | CYP19A1 (0.81) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Pinocembrin SCHEMBL17651823 | 0.88 | CYP19A1 (0.81) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL72954 | 0.88 | CYP19A1 (0.81) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL20570 | 0.87 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399511-B2 | Two types of crystalline of pinocembrin, their preparation and their use for manufacture of pharmaceutical compositions | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2013-03-19 | — | — | US | disclosed |
| US-20110213024-A1 | TWO TYPES OF CRYSTALLINE OF PINOCEMBRIN, THEIR PREPARATION AND THEIR USE FOR MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | CSPC Zhongqi West Road Shijazhuang (CN) | 2011-09-01 | — | — | US | disclosed |
| EP-2360152-A1 | TWO TYPES OF CRYSTALLINE OF PINOCEMBRIN: A AND B, THEIR PREPARATION AND THEIR USE FOR MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213024-A1 | TWO TYPES OF CRYSTALLINE OF PINOCEMBRIN, THEIR PREPARATION AND THEIR USE FOR MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | PNN, CALU, NGF | CYP19A1 3274/4885CYP3A4 1310/4885CYP1A1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.